The FDA reported on April 25 that two companies that manufacture Phenylephrine are also experiencing a delay in the drug’s production. Baxter, one of the manufacturers, has accelerated production and anticipates having Phenylephrine available in mid-May.
Sandoz, the other manufacturer, is experiencing a back order of 10mL and 5mL vials of Phenylephrine HCI injection due to excess demand for the drug. The company anticipates more availability by the end of May.
According to the report, American Regent Manufacturers’ parent company, Luitpold Pharmaceuticals, is developing a plan to allow manufacturing and distribution to resume as soon as possible.
Read the ASA release on Phenylephrine.
Related Articles on Drug Shortages:
Hospira Producing Propofol Again
American Society of Anesthesiologists Conducts Survey on Drug Shortages
6 Strategies for Surgery Centers to Address Drug Shortages
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
